Inventor · disambiguated record
Oliver Rosen
Also filed as: ROSEN OLIVER
18 granted patents·12 pending applications·302 citations·filing 2007–2025
95Inventor score
Files withDECIPHERA PHARMACEUTICALS LLC23STEMCELL TECHNOLOGIES CANADA INC3SQZ BIOTECHNOLOGIES CO2MERCK PATENT GMBH1REIFFEN KARL-AUGUST1
Top patents by PatentIndex Score
30 records- 0198US11813251B2Methods of treating gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Granted Nov 14, 2023·15 cites·4 claims
- 0298US11576904B2Methods of treating gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Granted Feb 14, 2023·33 cites·1 claims
- 0398US11534432B2Methods of treating gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Granted Dec 27, 2022·34 cites·4 claims
- 0498US11529336B2Methods of treating gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Granted Dec 20, 2022·31 cites·2 claims
- 0598US11433056B1Methods of treating gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Granted Sep 6, 2022·31 cites·3 claims
- 0698US11426390B2Methods of treating gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Granted Aug 30, 2022·36 cites·6 claims
- 0798US11344536B1Methods of treating gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Granted May 31, 2022·37 cites·3 claims
- 0898US11266635B2Methods of treating gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2021·Granted Mar 8, 2022·39 cites·3 claims
- 0998US10966966B2Methods of treating gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2020·Granted Apr 6, 2021·46 cites·3 claims
- 1092US12318373B2Methods of treating gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2024·Granted Jun 3, 2025·0 cites·3 claims
- 1192US12295944B2Methods of treating gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2024·Granted May 13, 2025·0 cites·1 claims
- 1290US12059410B2Methods of treating gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Aug 13, 2024·0 cites·2 claims
- 1390US12059411B2Methods of treating gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Aug 13, 2024·0 cites·3 claims
- 1490US12023325B2Methods of treating gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Jul 2, 2024·0 cites·6 claims
- 1590US12023327B2Methods of treating gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Jul 2, 2024·0 cites·2 claims
- 1690US12023326B2Methods of treating gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Jul 2, 2024·0 cites·1 claims
- 1785US11969414B2Methods of treating gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Granted Apr 30, 2024·0 cites·1 claims
- 1885US2025367176A1Methods of treating gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2025·Application pending·0 cites
- 1979US2022370423A1Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alphaDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Application pending·0 cites
- 2078US2022370424A1Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alphaDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Application pending·0 cites
- 2176US2022031678A1Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alphaDECIPHERA PHARMACEUTICALS LLC·Filed 2021·Application pending·0 cites
- 2271US2021015801A1Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alphaDECIPHERA PHARMACEUTICALS LLC·Filed 2020·Application pending·0 cites
- 2370US2025319174A1Methods for treating cancers with modified pbmcsSTEMCELL TECHNOLOGIES CANADA INC·Filed 2025·Application pending·0 cites
- 2469US2025339526A1Methods for treating cancer with enhanced antigen presenting cellsSTEMCELL TECHNOLOGIES CANADA INC·Filed 2023·Application pending·0 cites
- 2567US2020129489A1Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alphaDECIPHERA PHARMACEUTICALS LLC·Filed 2017·Application pending·0 cites
- 2667US2022296691A1Methods for treating cancer with activating antigen carriersSQZ BIOTECHNOLOGIES CO·Filed 2021·Application pending·0 cites
- 2766US2025326802A1Methods for treating cancer with activating antigen carriersSTEMCELL TECHNOLOGIES CANADA INC·Filed 2025·Application pending·0 cites
- 2865US2022233677A1Methods for treating cancers with modified pbmcsSQZ BIOTECHNOLOGIES CO·Filed 2021·Application pending·0 cites
- 2955US2007202101A1Combination therapy using anti-EGFR antibodies and anti-hormonal agentsMERCK PATENT GMBH·Filed 2007·Application pending·0 cites
- 3035US8445219B2Method of determination of receptor binding saturation effected by monoclonal antibodiesREIFFEN KARL-AUGUST·Filed 2009·Granted May 21, 2013·0 cites·17 claims
Join the waitlist — get patent alerts
Get an alert when Oliver Rosen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →